Blog Header

In: OST-122

February 2020
Oncostellae received regulatory approval to start a proof of concept study with OST-122 in patients with ulcerative colitis
febrero 21, 2020

Oncostellae has received permission from the regulator to start a Phase 2a study with OST-122 in patients suffering from ulcerative colitis….

Read More
May 2019
OST-122 has successfully completed a Phase 1b trial in HV and has proved to be GI-restricted and well tolerated up to 1200 mg after multiple dosing
febrero 20, 2020

Following a successful randomized, double-blind, placebo-controlled Phase 1a clinical trial in healthy volunteers which was carried out at the Sant Pau…

Read More